Prelude Therapeutics Inc
For the period ended Dec 31, 2025. Filed Mar 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 10, 2026
PRLD$3.760.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets as of December 31, 2025 and 2024
BALANCE SHEETS
| December 31, | ||
|---|---|---|
| (in thousands, except share and per share data) | 2025 | 2024 |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $35,256 | $12,474 |
| Marketable securities | 67,958 | 121,140 |
| Prepaid expenses and other current assets | 2,478 | 2,281 |
| Total current assets | 105,692 | 135,895 |
| Restricted cash | 3,235 | 4,044 |
| Property and equipment, net | 5,113 | 6,767 |
| Right-of-use asset | 27,165 | 28,699 |
| Prepaid expenses and other non-current assets | 110 | 110 |
| Total assets | $141,315 | $175,515 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $3,983 | $7,732 |
| Accrued expenses and other current liabilities | 12,533 | 15,209 |
| Deferred revenue | 33,734 | — |
| Operating lease liability | 2,744 | 2,492 |
| Finance lease liability | — | 208 |
| Total current liabilities | 52,994 | 25,641 |
| Deferred revenue, net of current portion | 1,798 | — |
| Other liabilities | 2,841 | 3,090 |
| Operating lease liability | 15,045 | 15,325 |
| Total liabilities | 72,678 | 44,056 |
| Commitments (note 8) | ||
| Stockholders’ equity: | ||
| Voting common stock, $0.0001 par value: 487,149,741 shares authorized; 48,225,493 and 42,298,859 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5 | 4 |
| Non-voting common stock, $0.0001 par value: 112,850,259 and 12,850,259 shares authorized at December 31, 2025 and 2024, respectively; 14,728,135 and 12,850,259 shares issued and outstanding at December 31, 2025 and 2024, respectively | 1 | 1 |
| Additional paid-in capital | 751,684 | 714,982 |
| Accumulated other comprehensive income | 8 | 35 |
| Accumulated deficit | (683,061) | (583,563) |
| Total stockholders’ equity | 68,637 | 131,459 |
| Total liabilities and stockholders’ equity | $141,315 | $175,515 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.